{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:18:00Z","timestamp":1787699880897,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic differences between plasma cell disorders reflect coordinated metabolic reprogramming within clonal plasma cells and the bone marrow microenvironment. We applied high-resolution MALDI\u2013FT-ICR mass spectrometry imaging (MSI) to archived FFPE bone-marrow biopsies from patients with MGUS-like bone marrows (defined as &lt;10% clonal plasma cells, including MGUS and solitary bone plasmacytoma with minimal marrow involvement (SBPmm)) and multiple myeloma (MM), integrated with matched bone marrow plasma metabolomics, to map spatial and systemic metabolic alterations. Spatial clustering delineated plasma-cell-rich niches, while Hill-based diversity and \u03b2-diversity metrics quantified intra- and inter-compartment heterogeneity. MM niches exhibited elevated 3-hydroxykynurenine, rewired tryptophan\u2013kynurenine flux, and increased nucleotide and bioactive lipid metabolism associated with proliferation. Notably, SBPmm samples displayed MM-like metabolic niches undetectable in bone marrow plasma alone, underscoring spatial heterogeneity. Cross-compartment integration revealed conserved metabolic signatures and systemic redistribution of key metabolites, consistent with ecological reorganization and niche divergence between MGUS-like and MM. These findings establish spatial metabolomics of biopsies as a framework to dissect intramedullary metabolic heterogeneity and enable metabolite-based risk stratification in plasma cell disorders.<\/jats:p>","DOI":"10.1038\/s41408-026-01525-8","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:24:52Z","timestamp":1781634292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Guoxing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6679-518X","authenticated-orcid":false,"given":"Yogesh","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitosugi","family":"Taro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-4023","authenticated-orcid":false,"given":"Axel Karl","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1525_CR1","first-page":"680","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos M-V, Zweegman S, et al. EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin. Oncol. 2025;22:680\u2013700.","journal-title":"Oncol."},{"key":"1525_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-023-01472-y","volume":"16","author":"F Sun","year":"2023","unstructured":"Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, et al. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023;16:70.","journal-title":"J Hematol Oncol"},{"key":"1525_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet."},{"key":"1525_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-024-01600-2","volume":"17","author":"F Zhang","year":"2024","unstructured":"Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, et al. Cancer-associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol. 2024;17:80.","journal-title":"J Hematol Oncol"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","volume":"9","author":"T Hu","year":"2024","unstructured":"Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther. 2024;9:268.","journal-title":"Signal Transduct Target Ther"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5:1267\u201384.","journal-title":"Nat Cancer"},{"key":"1525_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02113-9","volume":"23","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Li Y, Zhao H. Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective. Mol Cancer. 2024;23:202.","journal-title":"Mol Cancer"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","volume":"17","author":"X Liu","year":"2024","unstructured":"Liu X, Peng T, Xu M, Lin S, Hu B, Chu T, et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J Hematol Oncol. 2024;17:72.","journal-title":"J Hematol Oncol"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-025-01699-x","volume":"18","author":"V Desantis","year":"2025","unstructured":"Desantis V, Andriano A, D\u00fcking T, Hartwig O, Ingravallo G, Biondo M, et al. Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease. J Hematol Oncol. 2025;18:47.","journal-title":"J Hematol Oncol"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/nprot.2016.081","volume":"11","author":"A Ly","year":"2016","unstructured":"Ly A, Buck A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat Protoc. 2016;11:1428\u201343.","journal-title":"Nat Protoc"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-025-08710-y","volume":"640","author":"H Cui","year":"2025","unstructured":"Cui H, Tejada-Lapuerta A, Brbi\u0107 M, Saez-Rodriguez J, Cristea S, Goodarzi H, et al. Towards multimodal foundation models in molecular cell biology. Nature. 2025;640:623\u201333.","journal-title":"Nature."},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41592-024-02392-6","volume":"21","author":"JB Nunes","year":"2024","unstructured":"Nunes JB, Ijsselsteijn ME, Abdelaal T, Ursem R, van der Ploeg M, Giera M, et al. Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling. Nat Methods. 2024;21:1796\u2013800.","journal-title":"Nat Methods"},{"key":"1525_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67105-3","volume":"10","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Broniowska K, Jessen E, Petterson XM, Bush AG, Gransee J, et al. Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy ofundetermined significance from multiple myeloma. Sci Rep. 2020;10:10250.","journal-title":"Sci Rep"},{"key":"1525_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41375-019-0558-x","volume":"34","author":"A Ray","year":"2020","unstructured":"Ray A, Song Y, Du T, Tai YT, Chauhan D, Anderson KC. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2020;34:567\u201377.","journal-title":"Leukemia."},{"key":"1525_CR15","first-page":"e359","volume":"5","author":"C Ludwig","year":"2015","unstructured":"Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW, et al. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiplemyeloma. Blood. Cancer J. 2015;5:e359.","journal-title":"Cancer J"},{"key":"1525_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013e548.","journal-title":"Lancet Oncol"},{"key":"1525_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01232-w","volume":"15","author":"S Zanwar","year":"2025","unstructured":"Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 2025;15:20.","journal-title":"Blood Cancer J"},{"key":"1525_CR18","doi-asserted-by":"publisher","first-page":"108413","DOI":"10.1016\/j.compbiomed.2024.108413","volume":"174","author":"S Bhattacharjee","year":"2024","unstructured":"Bhattacharjee S, Saha B, Saha S. Symptom-based drug prediction of lifestyle-related chronic diseases using unsupervised machine learning techniques. Comput Biol Med. 2024;174:108413.","journal-title":"Comput Biol Med"},{"key":"1525_CR19","doi-asserted-by":"publisher","first-page":"216924","DOI":"10.1016\/j.canlet.2024.216924","volume":"592","author":"D Xiong","year":"2024","unstructured":"Xiong D, Wang Q, Wang WM, Sun ZJ. Tuning cellular metabolism for cancer virotherapy. Cancer Lett. 2024;592:216924.","journal-title":"Cancer Lett"},{"key":"1525_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/15548627.2023.2247310","volume":"20","author":"M Borsa","year":"2024","unstructured":"Borsa M, Obba S, Richter FC, Zhang H, Riffelmacher T, Carrelha J, et al. Autophagy preserves hematopoietic stem cells by restraining MTORC1-mediated cellular anabolism. Autophagy. 2024;20:45\u201357.","journal-title":"Autophagy."},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hon.3108","volume":"41","author":"A Asano","year":"2023","unstructured":"Asano A, Ri M, Masaki A, Maeda Y, Tachita T, Hirade K, et al. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients. Hematol Oncol. 2023;41:424\u201333.","journal-title":"Hematol Oncol"},{"key":"1525_CR22","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/1078-0432.CCR-24-2000","volume":"31","author":"E Morelli","year":"2025","unstructured":"Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, et al. Targeting acetyl-CoA carboxylase suppresses de novo lipogenesis and tumor cell growth in multiple myeloma. Clin Cancer Res. 2025;31:1975\u201387.","journal-title":"Clin Cancer Res"},{"key":"1525_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1080\/15548627.2023.2208931","volume":"20","author":"H Leng","year":"2024","unstructured":"Leng H, Simon AK, Horwood NJ. Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease. Autophagy. 2024;20:930\u20132.","journal-title":"Autophagy."},{"key":"1525_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35358-3","volume":"13","author":"H Leng","year":"2022","unstructured":"Leng H, Zhang H, Li L, Zhang S, Wang Y, Chavda SJ, et al. Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease. Nat Commun. 2022;13:7868.","journal-title":"Nat Commun"},{"key":"1525_CR25","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1016\/j.cell.2024.05.011","volume":"187","author":"DH Tran","year":"2024","unstructured":"Tran DH, Kim D, Kesavan R, Brown H, Dey T, Soflaee MH, et al. De novo and salvage purine synthesis pathways across tissues and tumors. Cell. 2024;187:3602\u2013e20.","journal-title":"Cell."},{"key":"1525_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275\u201394.","journal-title":"Nat Rev Cancer"},{"key":"1525_CR27","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","volume":"120","author":"M Cea","year":"2012","unstructured":"Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulatedkinase (ERK1\/2) inhibition. Blood. 2012;120:3519\u201329.","journal-title":"Blood."},{"key":"1525_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41375-023-02071-z","volume":"38","author":"C Pfeiffer","year":"2024","unstructured":"Pfeiffer C, Grandits AM, Asnagli H, Schneller A, Huber J, Zojer N, et al. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1. Leukemia. 2024;38:181\u201392.","journal-title":"Leukemia."},{"key":"1525_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood.2024025690","volume":"145","author":"R Nair","year":"2025","unstructured":"Nair R, Vu AH, Freer AK, Bhatia KS, Wang D, Savani MR, et al. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood. 2025;145:732\u201347.","journal-title":"Blood."},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","volume":"11","author":"I Oudaert","year":"2022","unstructured":"Oudaert I, Van der Vreken A, Maes A, De Bruyne E, De Veirman K, Vanderkerken K, et al. Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. Exp Hematol Oncol. 2022;11:49.","journal-title":"Exp Hematol Oncol"},{"key":"1525_CR31","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139:876\u201388.","journal-title":"Blood."},{"key":"1525_CR32","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2024027496","volume":"146","author":"F Navarro","year":"2025","unstructured":"Navarro F, Lozano T, Fuentes-Garc\u00eda A, S\u00e1nchez-Moreno I, Larrayoz M, Justicia P, et al. Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiplemyeloma. Blood. 2025;146:2931\u201344.","journal-title":"Blood."},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1182\/blood.2024026227","volume":"146","author":"MV Dhodapkar","year":"2025","unstructured":"Dhodapkar MV, Paiva B. Immune alterations in myeloma evolution and outcomes: quo vadis? Blood. 2025;146:1041\u201350.","journal-title":"Blood."},{"key":"1525_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00502-8","volume":"11","author":"M Chen","year":"2023","unstructured":"Chen M, Jiang J, Hou J. Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications. Biomark Res. 2023;11:55.","journal-title":"Biomark Res"},{"key":"1525_CR35","doi-asserted-by":"crossref","unstructured":"Stone TW, Williams RO Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023;44:442\u201356.","DOI":"10.1016\/j.tips.2023.04.006"},{"key":"1525_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2967\/jnumed.121.262609","volume":"63","author":"JR Salas","year":"2022","unstructured":"Salas JR, Clark PM. Signaling pathways that drive 18F-FDG accumulation in cancer. J Nucl Med. 2022;63:659\u201363.","journal-title":"J Nucl Med"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/cancers15153764","volume":"15","author":"K Dunphy","year":"2023","unstructured":"Dunphy K, Bazou D, Henry M, Meleady P, Miettinen JJ, Heckman CA, et al. Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifiesdistinct protein and metabolite signatures. Cancers (Basel). 2023;15:3764.","journal-title":"Cancers (Basel)"},{"key":"1525_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cmet.2017.08.006","volume":"26","author":"J Simcox","year":"2017","unstructured":"Simcox J, Geoghegan G, Maschek JA, Bensard CL, Pasquali M, Miao R, et al. Global analysis of plasma lipids identifies liver-derived acylcarnitines as a fuel source for brown fat thermogenesis. Cell Metab. 2017;26:509.e6.","journal-title":"Cell Metab"},{"key":"1525_CR39","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/jcsm.12817","volume":"12","author":"S Catanese","year":"2021","unstructured":"Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, et al. Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2021;12:2101\u201310.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1525_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","volume":"185","author":"Y Liu","year":"2025","unstructured":"Liu Y, Parks AL. Diagnosis and management of monoclonal gammopathy of undetermined significance: a review. JAMA Intern Med. 2025;185:450\u20136.","journal-title":"JAMA Intern Med"},{"key":"1525_CR41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41698-023-00434-4","volume":"7","author":"J Wang","year":"2023","unstructured":"Wang J, Sun N, Kunzke T, Shen J, Zens P, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma. NPJ Precis Oncol. 2023;7:114.","journal-title":"NPJ Precis Oncol"},{"key":"1525_CR42","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41:1032.e4.","journal-title":"Cancer Cell"},{"key":"1525_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma\u2014opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19:223\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"1525_CR44","doi-asserted-by":"publisher","first-page":"e167629","DOI":"10.1172\/JCI167629","volume":"133","author":"MH Robinson","year":"2023","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, et al. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest. 2023;133:e167629.","journal-title":"J Clin Invest"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01525-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01525-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01525-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:44:04Z","timestamp":1787697844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01525-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01525-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"143"}}